Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GPX4 | P36969 | 2/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960902 | 1.00 | ABCB1 (0.64) | ABCB1ABCG2PDE4BDRD2DRD4 | |
| Sulfuric Acid SCHEMBL1960857 | 0.97 | ABCB1 (0.65) | ABCB1ABCG2PDE4BDRD2DRD4 | |
| Sulfuric Acid SCHEMBL1960854 | 0.97 | ABCB1 (0.65) | ABCB1ABCG2PDE4BDRD2DRD4 | |
| SCHEMBL1956947 | 0.95 | ABCB1 (0.71) | ABCB1ABCG2PDE4BDRD2DRD4 | |
| SCHEMBL1956943 | 0.95 | ABCB1 (0.71) | ABCB1ABCG2PDE4BDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL1959916 | 0.94 | ABCB1 (0.69) | ABCB1ABCG2PDE4BDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL1959914 | 0.94 | ABCB1 (0.69) | ABCB1ABCG2PDE4BDRD2DRD4 | |
| Nitric Acid SCHEMBL1956810 | 0.90 | ABCB1 (0.63) | ABCB1ABCG2PDE4BDRD2DRD4 | |
| Nitric Acid SCHEMBL1956808 | 0.90 | ABCB1 (0.63) | ABCB1ABCG2PDE4BDRD2DRD4 | |
| SCHEMBL1960898 | 0.89 | ABCB1 (0.63) | ABCB1ABCG2PDE4BDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-8697742-B2 | BCRP/ABCG2 inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2332905-A1 | BCRP/ABCG3 Inhibitor | Kabushiki Kaisha Yakult Honsha (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1864972-A1 | BCRP/ABCG2 INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253656-A1 | BCRP/ABCG2 INHIBITOR | ABCC1, ABCB1, BRCA1 | DRD2 2054/4885DRD4 3478/4885DRD3 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.